Kurs & Likviditet
|Lista||First North Stockholm|
|2022-05-20||Ordinarie utdelning AMNI 0.00 SEK|
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that an abstract with new promising preclinical data on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) with mesenchymal stem cells (MSC) has been accepted for a poster presentation at the 16th International Conference on Regenerative Biology and Engineering (ICRBE) taking place on July 28-29 in Zurich, Switzerland.
The abstract, titled “Amniotic Fluid Mesenchymal Stem Cells Selected for Neural Specificity Ameliorates Chemotherapy Induced Hearing Loss and Pain Perception”, will be presented by Amniotic’s COO Jan Talts at ICRBE. Other authors include Kåre Engkilde, CEO of Amniotics. The presentation includes preclinical results showing that treatment with MSC selected for neural specificity (CogniStemTM) have significant positive efficacy on chemotherapy-induced hearing loss and chemotherapy-induced neuropathic pain.
“The results show the potential wide usages of tissue specific/relevant mesenchymal stem cells from amniotic fluid as treatment in connection with cancer therapy and represent further validation of Amniotics platform and our therapeutic approach. We’re excited about the data presented and will now evaluate how to leverage on these findings,” says Jan Talts, COO at Amniotics.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by anti-neoplastic agents, with a prevalence between 19 and 85 percent. Clinically, CIPN is a mostly sensory neuropathy leading to pain and to motor and autonomic changes. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors, especially because currently there is no single effective method of preventing CIPN. Hearing loss is the most common form of sensory impairment in humans and can be caused by ototoxic chemical compounds such as chemotherapy (platinum-based antineoplastic agents).